

31 July 2017

Australian Securities Exchange
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

Alcidion Group Limited Announces Board Renewal

Adelaide, South Australia, 31 July 2017 - Alcidion Group Limited (ASX: **ALC**), a global leader in Clinical Informatics, today announced the appointment of two new Non-Executive Directors as part of a board renewal process.

Mr Geoff Rohrsheim, a software, services and technology entrepreneur, and Ms Rebecca Wilson, a highly experienced investor relations and corporate advisor with two decades' experience in the healthcare industry, have been appointed to the Board of Directors, effective immediately.

The Board has accepted the resignation of Mr Brian Leedman and Mr Nathan Buzza who have served on the Alcidion Board for one and four years respectively. Mr Buzza will continue in an executive capacity with Alcidion Group until December 2017 to assist in transitioning his roles and responsibilities.

Mr Raymond Blight, Alcidion's Executive Chairman said: "The Board would like to thank Nathan and Brian for their valued contribution to the Company and wish them the very best in their future endeavours. Over the past twenty-four months, Alcidion has made great progress and we are now well placed to accelerate the commercialisation of our technologies."

"We would also like to welcome two highly credentialed professionals to our board. Geoff is a leader in ICT and has a demonstrable track record in both innovation invention and commercialisation. He understands deeply the importance of the intersection of technology and industry, in our field. Rebecca is one of the most experienced investor relations specialists in our industry and in particular works alongside boards and executive teams of high growth potential companies."

Mr Rohrsheim is a former EY Entrepreneur of the Year winner and has founded three start-ups that have featured in the BRW Fast 100. His latest venture, Kloud Solutions (www.kloud.com.au) grew rapidly in five years to have more than 170 staff. Kloud was sold to Telstra in Feb 2016. Geoff shares his executive time across his own co-founded startups being Hatch Creations, Chamonix IT Consulting, Cevo and Expose Data.

He is a passionate advocate for South Australian innovation and chairs the Technology and Innovation sub-committee at RAA, is a member of the Australia Post Stakeholder Council and an advisory board member of Rivergum Homes. He has BE (Hons), AssDip Comp Apps, MEngSc, GAICD.

Ms Wilson is currently CEO of WE Buchan and has dedicated the last 18 years to working within the health and technology sectors providing advice on stakeholder communications, issues management, investor and corporate relations, and business strategy to private and public companies, research institutes, governments, and asset / wealth managers. She has a strong network of investors in Australia, South East Asia and the US and has a deep knowledge and experience of corporate governance having worked, almost exclusively, with ASX companies over the last two decades. She has a BA (Journalism) and Post-Graduate Certificate in Applied Finance and Investment.

Yours faithfully,



Raymond Blight

Chief Executive Officer & Chairman

ENDS

For further information, please contact:

Nathan Buzza, Executive Director

Ph: +61 (0) 488862222

Alcidion Group Limited

nathan.buzza@alcidion.com

Ray Blight, Chief Executive Officer

Ph: +61 (08) 8208 4600

Alcidion Group Limited

ray.blight@alcidion.com

About Alcidion

Alcidion Group Limited (ASX: **ALC**) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	GEOFF ROHSHEIM
Date of appointment	31 JULY 2017

Part 1 - Director's relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
NIL

Appendix 3X Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	REBECCA WILSON
Date of appointment	31 JULY 2017

Part 1 - Director's relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
NIL

Appendix 3X Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	BRIAN LEEDMAN
Date of last notice	13/4/2017
Date that director ceased to be director	31/7/2017

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
5,000,000 – UNLISTED OPTIONS (with an exercise price of \$0.06; exercisable after release of Appendix 4E for year ending 30 June 2017; and expiring 30 JUNE 2020)
5,000,000 – UNLISTED OPTIONS (with an exercise price of \$0.08; exercisable after release of Appendix 4E for year ending 30 June 2018; and expiring 30 JUNE 2020)

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
NIL	

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	NATHAN BUZZA
Date of last notice	23/12/2016
Date that director ceased to be director	31/07/2017

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
NIL

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
SECURITIES HELD BY ALLURE CAPITAL PTY LTD AS TRUSTEE OF THE BUZZA FAMILY TRUST	16,717,243 - FULLY PAID ORDINARY SHARES (escrowed for 24 months until 25 th February 2018)
MR. BUZZA IS A DIRECTOR AND SHAREHOLDER OF ALLURE CAPITAL PTY LTD AND A BENEFICIARY OF THE BUZZA FAMILY TRUST	2,458,828 - FULLY PAID ORDINARY SHARES (voluntary escrowed until 28 th February 2018)
	10,947,075 - CLASS A CONTINGENT SHARE RIGHTS (\$10M REVENUE TRIGGER WITHIN 2 YEARS FROM 29 FEBRUARY 2016)
	10,947,075 - CLASS B CONTINGENT SHARE RIGHTS (\$15M REVENUE TRIGGER WITHIN 3 YEARS FROM 29 FEBRUARY 2016)
	2,500,000 - CALL OPTION OVER FULLY PAID ORDINARY SHARES @ \$0.05 EXERCISABLE AFTER RELEASE OF APPENDIX 4E FOR FINANCIAL YEAR ENDING 30 JUNE 2017

Part 3 – Director's interests in contracts

Detail of contract	TRANSFER AND OPTION DEED DATED 21 DECEMBER 2016 BETWEEN MR BUZZA, ALLURE CAPITAL PTY LTD, ALCIDION GROUP LIMITED, BPSE MEDICAL TECHNOLOGY PTY LTD AS TRUSTEE FOR THE BSPE MEDICAL TECHNOLOGY TRUST, RAYMOND HOWARD BLIGHT AND MALCOLM PRADHAN
Nature of interest	CALL OPTION OVER 2,500,000 FULLY PAID ORDINARY SHARES @ \$0.05 EXERCISABLE AFTER RELEASE OF APPENDIX 4E FOR FINANCIAL YEAR ENDING 30 JUNE 2017

+ See chapter 19 for defined terms.

Appendix 3Z
Final Director's Interest Notice

Name of registered holder (if issued securities)	BPSE MEDICAL TECHNOLOGY PTY LTD AS TRUSTEE FOR THE BSPE MEDICAL TECHNOLOGY TRUST (RESPECT OF 1,000,000 SHARES) RAYMOND HOWARD BLIGHT (IN RESPECT OF 620,036 SHARES) MALCOLM PRADHAN (IN RESPECT OF 879,964 SHARES)
No. and class of securities to which interest relates	2,500,000 FULLY PAID ORDINARY SHARES

+ See chapter 19 for defined terms.

11/3/2002